Presentations by Program

Search by Program

Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Adult Subjects

K.A. Rodvold (University of Illinois at Chicago), ASM Microbe 2018

Evaluation of Pharmacokinetics/Pharmacodynamics of the Novel β-lactamase Inhibitor, ETX2514, in Combination with Sulbactam Against Acinetobacter baumannii

John O'Donnell, ASM Microbe 2018

Safety and Pharmacokinetics (PK) in Humans of Intravenous ETX2514, a β–lactamase Inhibitor (BLI) which Broadly Inhibits Ambler Class A, C, and D β–lactamases

J. Lickliter, K. Lawrence, J. O’Donnell, and R. Isaacs, ID Week 2017

The Antibacterial Activity of Sulbactam and the Novel β–lactamase Inhibitor ETX2514 Combined with Imipenem or Meropenem Against Recent Clinical Isolates of Acinetobacter baumannii and Pseudomonas aeruginosa

Sarah McLeod, ASM Microbe 2017

Reversibility of β–lactamase inhibition by the broad-spectrum diazabicyclooctenone serine β–lactamase inhibitor ETX2514

Adam Shapiro, ASM Microbe 2017

ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens

Ruben Tommasi, ECCMID 2017

Discovery of ETX2514, a novel, rationally designed inhibitor of Class A, C and D β–lactamases, for the treatment of Gram-negative infections

Thomas Durand-Reville, ACS 2017

ETX2514 restoration of sulbactam activity against multidrug resistant Acinetobacter baumannii correlates with β-lactamase inhibition in vitro and in vivo

Alita Miller, ECCMID 2017

Pathogen-directed strategies at Entasis Therapeutics

Alita Miller, SDRI 2017

Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broad-spectrum activity against Class A, C and D enzymes

Alita Miller, Superbugs & Superdrugs USA 2016